title: The 2',4',6'-trihydroxyacetophenone isolated from Myrcia multiflora has antiobesity and mixed hypolipidemic effects with the reduction of lipid intestinal absorption.
abstract: This study evaluated the hypolipidemic and antiobesity effects of phloroacetophenone (2',4',6'-trihydroxyacetophenone, THA) isolated from Myrcia multiflora and their relationship with triglyceride (TG) intestinal absorption and pancreatic lipase activity inhibition. The hypolipidemic effect of THA was evaluated by acute (Triton WR-1339 treatment) and chronic assay (high-fat diet treatment), the antiobesity effect was evaluated by chronic assay (high-fat diet treatment), while the inhibition of enzymatic activity of pancreatic lipase was measured in the intestinal tissue of mice treated with high olive oil concentration. In the acute assay, THA caused greater total cholesterol (37 %) and triglyceride (46 %) serum level reduction than lovastatin (32 and 1 %), a HMG-CoA reductase inhibitor or orlistat (26 and 34 %), a gastrointestinal lipase inhibitor. In addition, in the chronic assay with a high-fat diet, THA reduced cholesterol and triglyceride levels (32 and 61 %, respectively) while lovastatin showed a decrease of 35 and 49 %, respectively. THA also caused a reduction in weight gain very similar to orlistat (40 and 38 %, respectively) when the animals were submitted to a high-fat diet. Moreover, THA showed a stronger and continuous pancreatic lipase inhibitory activity when compared with orlistat, causing inhibition of this enzyme during 6 hours associated to a significant reduction of triglyceride serum levels. The IN VIVO antiobesity and hypolipidemic effects of THA may be partly mediated by delaying the intestinal absorption of dietary fat by inhibiting pancreatic lipase activity.
authors.affiliation: Department of Biochemistry, CCB, Federal University of Santa Catarina, Florianópolis, SC, Brazil.
authors.forename: Eduardo Antonio
authors.initials: EA
authors.lastname: Ferreira
authors.forename: Eliana Fortes
authors.initials: EF
authors.lastname: Gris
authors.forename: Jussara Matos
authors.initials: JM
authors.lastname: Rebello
authors.forename: João Francisco
authors.initials: JF
authors.lastname: Correia
authors.forename: Luis Flávio
authors.initials: LF
authors.lastname: de Oliveira
authors.forename: Danilo Wilhelm
authors.initials: DW
authors.lastname: Filho
authors.forename: Rozangela Curi
authors.initials: RC
authors.lastname: Pedrosa
mesh_terms: D000098:Acetophenones / Q000302:isolation & purification / Q000494:pharmacology*; D000818:Animals; D019440:Anti-Obesity Agents / Q000302:isolation & purification / Q000494:pharmacology*; D002784:Cholesterol / Q000097:blood; D059305:Diet, High-Fat; D005960:Glucosides / Q000302:isolation & purification / Q000494:pharmacology*; D000960:Hypolipidemic Agents; D007408:Intestinal Absorption / Q000187:drug effects*; D007783:Lactones / Q000494:pharmacology; D008049:Lipase / Q000187:drug effects / Q000378:metabolism; D008055:Lipids / Q000097:blood; D008148:Lovastatin / Q000494:pharmacology; D008297:Male; D051379:Mice; D031641:Myrica / Q000737:chemistry*; D009765:Obesity / Q000378:metabolism; D000077403:Orlistat; D010179:Pancreas / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D010936:Plant Extracts / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000097:blood / Q000378:metabolism*; D015430:Weight Gain / Q000187:drug effects
chemical_list: D000098:Acetophenones; D019440:Anti-Obesity Agents; D005960:Glucosides; D000960:Hypolipidemic Agents; D007783:Lactones; D008055:Lipids; D010936:Plant Extracts; D014280:Triglycerides; C107067:2,4,6-trihydroxyacetophenone; D000077403:Orlistat; D002784:Cholesterol; D008148:Lovastatin; D008049:Lipase